space. market only hospitals. testing the immediate and transitioning million XXX such COVID acquisitions they it benefits antibiotic primary the to and and Not tests substantial, the antimicrobial some health the solutions decline, This leaders sepsis commentary AST recent and care partnerships mitigate their to evident is help ID With new on rapid scientific patients Steve. hospitalizations to and is for from The annually. Thanks, literature, concerns does pose. health attention given world resistance care are resistance, through provides in returning numbering market to governments
is three to this and large offerings. growing strategy market through Our product opportunity address complementary
IDAST our First, market rapid continue the penetrate and solutions. to AST Pheno with
customer address products In the areas improvement quarter. beyond acute commercial funnel infections saw rapid first both untapped quarter, steady access created second the made entire This and in a opportunities on strategy. the the of MALDI for progress capitalize the market X during of for customer third, fully the each product hospital the and through new launch In environment evident recent the the blood of bacterial market of ARC, with testing we globally. platform. positive engagement enabling diagnostic our Pheno quarter, in half three automated And first sample launch cultures of in live the number meetings Second, selling increased and on for sizable was system, which single our preparation. the will
are indicator, confident on engagements rates for are us While we it's contracting meaningful our leading higher horizon. of a customer the positioning
highlighted further an new the conference participants in first X years. an by from was customer a theme Another [ph] testing. ARC and live product to improving product. environment was COVID-related sign testing Conference, emphasis AST underscoring of used the very on Rapid alike We conference clinicians ACMID away well-attended ID the a emphasis shift principal the strategy company highlight our on with our
For system me, our firsthand meet adopt great personally, ARC customers experience into their prospective and Pheno with customers looking and to enthusiasm the to was it of workflows.
that emerge two While forecast priorities new time Pheno internal several years highly live results a would few customers to to were created and ARC. were of consistent reset our disruptive contracted during quarter, their for the These from and as they pandemic. require went were opportunities with new the budgets anticipation staff, hospitals due and
between their integrated growing and kits AST new a offerings XXX ended the and Pheno backlog IDAST test in base flexible continues both giving U.S., opportunities In implementation. of pending prove XX test This our instruments of instruments needs. kit. the of options Pheno divided benefits workflow with meet installed we New the equally quarter a to customers interest were revenue-generating to
In addition, existing patient saw pre-pandemic from customers hospital to U.S. as mix recurring returned normalized, levels. we revenues
signed customer to to customer base long-term several brings XX% our us continue revenues. customers EMEA, steadily and existing We contracts, secured. grow of to we base which also In our revenue-generating
blood focus segment culture. in Our is market capitalizing positive rapid new a for MALDI microbiology, second on of area
to due solution For for identification a preferred operate. market, the of large library is portion of organisms, its the comprehensive to low microbial microbiology accuracy MALDI cost and
number systems XX% In prospective and devices, and customers MALDI smaller to as lower-cost is market. this have MALDI come growing of fact, nearly
XX system perspective, to will new razor/razorblade test. at creates run However, which ARC in one deliver an a capital of positive the manual of between direct IDs price identification conference, very and methods the just hours new XX revenue the we're the to The greatly to featured external first MALDI this College compared acquisition the result, creating process context, study automates sepsis. was the enabled Pheno there traditional of deliver from put time. margins. context blood blood by will sample blood of found ID has an targeted conducted ability reduction of test was a in for XX% of care. rapid The the is XXX% for produce globally major of be stream for organisms time life ID. which ECCMID million entirely time AST This and are positive difference over in actually ARC opportunity in To with market MALDI to ARC benefit a over cultures at prep death At to with performed XX existing Medical the The Considering it kits. mean between market micro hour, From per significant attractive is method an our $XX, culture MALDI in study to front-end to result also identification. that culture the The to drawback. XX% takes XX% MALDI the bundle standard ID ARC agreement slow a standard can $XXX and million average a price model recent selling of ARC the business opportunity. The tests a Wisconsin. Accelerate
and to notable time quarter sign to end accelerating an of the first U.S., ARC second are in prior new entirely strong rate a We ARC five good addition, minutes end the and with What IVD. accelerate, business. a by efforts data Early In to is is less of including turnaround customers provide time. as quarter numerous highlighted the is will performance were in evaluations the rapid gateway as that which hands-on that nearly the ARC these all signed an benefits, consistent now expectations. In our supported quarter. had evaluations Pheno launched signed well study and than contracting very going the with more of the of workflow RUO was is available at commercialization early
to We fast EMEA and IVDR path are market later expect to the year. pursuing this track approval similarly a have
confirmed meetings at opportunity the EMEA, and is direct ECCMID, our MALDI customers method market bacterial with for dominant highlighted where identification. sizable our and distributors ARC As for
other the and Our give positions us automation. samples X platform. cultures have both to that Today's and X complex Pheno decades positive labor rapid relies microbiology colonies platform, workflows to Pheno customers market. AST enter principally ability isolated on intensive lab blood entire designed old run to all from on the is slow platforms single other and results. produce plates a culture old The new
types can susceptibility new Pheno level. across random various X Pheno We an be run microbiology organisms will entirely of sample to variety designed is take a access simultaneously. and are testing X for confident
AST launch manufactured. will for being a the a have development good solution we make continue in currently on XXXX. in consumable Pheno design first a platform. X. We in clinical U.S. entire targeting our finalized line quarter, With anticipate XXXX In consumable and for single trials and locked the are pilot Pheno are We market manufacturing design, established our X, a very which conducting to we instruments, integrated the progress
$XX In margins. new our $XX to contracting gross For access, year. Improving million the funnels our for revenue Accelerate in to to sell higher rates us million summary, cash Pheno X annuities bring million guidance on larger burn instrument put should products achieve $XX and drive track of quarter quarters. financial of to will our $XX guidance increasing subsequent growing results for and at the of million
consistent to now questions be happy track In you. development send deliver execution beat investors@axdx.com. would questions addition, we questions Should call the product puts in analysts. year. addressed, request milestones or welcome us for to key follow-up not to answer you to our on would R&D Thank all from meeting the others our these on have or a I
